Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | OPRL1 | P41146 | 11/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 11/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 10/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 10/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | NPY1R | P25929 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4341092 | 0.88 | OPRL1 (0.41) | SMN1; SMN2OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL4341190 | 0.86 | OPRL1 (0.43) | SMN1; SMN2OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL4322729 | 0.85 | KCNA3 (0.40) | SMN1; SMN2OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL4334115 | 0.82 | OPRL1 (0.48) | OPRL1OPRM1OPRD1OPRK1ALDH1A1 | |
| SCHEMBL4318217 | 0.79 | ADRA1D (0.40) | OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL4331690 | 0.75 | OPRM1 (0.43) | OPRL1OPRM1OPRD1OPRK1CYP3A4 | |
| SCHEMBL4332987 | 0.73 | OPRD1 (0.49) | OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL4326114 | 0.73 | OPRM1 (0.43) | SMN1; SMN2OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL4333175 | 0.73 | OPRM1 (0.43) | SMN1; SMN2TSHROPRL1OPRM1OPRD1 | |
| SCHEMBL4325746 | 0.73 | LMNA (0.48) | SMN1; SMN2OPRL1OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | ASTRAZENECA AB (SE) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | GRIN1, GRM1, GRIN3A | SMN1; SMN2 1220/4885TSHR 240/4885OPRL1 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.